阿巴西普术前停药时机与择期关节置换术后结局风险
该回顾性队列研究利用美国Medicare和Truven MarketScan行政数据(2006年1月至2015年9月),评估类风湿关节炎患者在择期髋或膝关节置换术前6个月内接受静脉阿巴西普治疗时,停药时机与术后30天住院感染、1年假体关节感染(PJI)等结局的关系。经过倾向加权分析,与继续用药相比,术前停用阿巴西普≥4周(一个给药间隔)并未降低住院感染、非尿路住院感染、PJI或30天再入院风险;而泼尼松>7.5 mg/天与住院感染风险升高相关。
要点
- 术前停用阿巴西普≥4周未降低30天住院感染或1年PJI风险。
- 停药<4周与4-8周或≥8周相比,术后感染及再入院风险无显著差异。
- 糖皮质激素>7.5 mg/天与住院感染风险升高相关(OR 2.19)。
核心结论
- 与继续静脉阿巴西普相比,术前停用≥4周(一个给药间隔)未降低住院感染、非尿路住院感染、PJI或30天再入院风险。
研究设计与样本
- 回顾性队列研究,使用美国Medicare和Truven MarketScan行政数据(2006年1月至2015年9月),纳入择期初次或翻修髋/膝关节置换术前6个月内接受静脉阿巴西普的成人类风湿关节炎患者。
- 共分析1,780例患者的1,939次手术,采用逆概率权重倾向加权比较不同停药时机的术后结局。
主要发现
- 术后30天住院感染175例(9.0%),非尿路住院感染115例(5.9%),PJI 39例(2.4/100人年),30天再入院114/1,815例(6.3%)。
- 停药<4周 vs 4-8周:住院感染OR 0.93(95%CI 0.65-1.34),非尿路住院感染OR 0.93(95%CI 0.60-1.44),PJI HR 1.29(95%CI 0.62-2.69),30天再入院OR 1.00(95%CI 0.65-1.54)。
- 停药<4周 vs ≥8周:各结局同样无显著差异。
- 糖皮质激素>7.5 mg/天与住院感染风险升高相关(OR 2.19,95%CI 1.28-3.77),与非尿路住院感染风险升高相关(OR 2.38,95%CI 1.22-4.64)。
临床怎么用
- 对于计划接受择期髋/膝关节置换的RA患者,术前停用静脉阿巴西普≥4周并未显示降低术后感染风险,停药决策需权衡疾病活动与感染风险。
- 围手术期应关注糖皮质激素剂量,>7.5 mg/天与住院感染风险升高相关。
局限性
- 回顾性队列设计基于行政数据,可能存在未测量混杂。
- 仅纳入静脉阿巴西普使用者,结果不能直接推广至皮下剂型或其他生物制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Guidelines recommend withholding biologic therapies before hip and knee arthroplasty, yet evidence to inform optimal timing is limited. The aim of this study was to determine whether withholding abatacept infusions is associated with lower risk of adverse postoperative outcomes. METHODS: This retrospective cohort study, which used US Medicare and Truven MarketScan administrative data from January 2006 to September 2015, evaluated adults with rheumatoid arthritis who received intravenous abatacept (precisely dated in claims data) within 6 months of elective primary or revision hip or knee arthroplasty. Propensity weighted analyses using inverse probability weights compared the risk of 30-day hospitalized infection and 1-year prosthetic joint infection (PJI) between patients with different abatacept stop timing (time between last infusion and surgery). Secondary analyses evaluated nonurinary hospitalized infections and 30-day readmissions. RESULTS: After 1,939 surgeries among 1,780 patients, there were 175 hospitalized infections (9.0%), 115 nonurinary hospitalized infections (5.9%), 39 PJIs (2.4/100 person-years), and 114/1,815 30-day readmissions (6.3%). There were no significant differences in outcomes with abatacept stop timing <4 weeks (1 dosing interval) versus 4-8 weeks (hospitalized infection odds ratio [OR] 0.93 [95% confidence interval (95% CI) 0.65-1.34]; nonurinary hospitalized infection OR 0.93 [95% CI 0.60-1.44]; PJI hazard ratio 1.29 [95% CI 0.62-2.69]; 30-day readmission OR 1.00 [95% CI 0.65-1.54]). Similarly, there were no significant differences in outcomes with abatacept stop timing <4 weeks versus ≥8 weeks. Glucocorticoid use >7.5 mg/day was associated with greater risk of hospitalized infection (OR 2.19 [95% CI 1.28-3.77]) and nonurinary hospitalized infection (OR 2.38 [95% CI 1.22-4.64]). CONCLUSION: Compared to continuing intravenous abatacept, withholding abatacept for ≥4 weeks (one dosing interval) before surgery was not associated with a lower risk of hospitalized infection, nonurinary hospitalized infection, PJI, or 30-day readmission.
引用
- George MD, Baker JF, Winthrop K, et al. Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative Outcomes. Arthritis Care Res (Hoboken). 2019. PMID: 30740938. doi:10.1002/acr.23843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。